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eligible for statin therapy as primary prevention. Whether these CVD risk thresholds should be individualized by age and
sex has not been explored.
OBJECTIVES This study evaluated the potential impact of incorporating age- and sex-speciﬁc CVD risk thresholds into
current cholesterol guidelines.
METHODS Using data from the Framingham Offspring Study, this study assessed current treatment recommendations
among age- and sex-speciﬁc groups in 3,685 participants free of CVD. Then, it evaluated how varying age- and sex-speciﬁc
10-year CVD risk thresholds for statin treatment affect the sensitivity and speciﬁcity for incident 10-year CVD events.
RESULTS Basing statin therapy recommendations on a 10-year ﬁxed risk threshold of 7.5% results in lower statin
consideration among women than men (63% vs. 33%; p < 0.0001), yet most of the study participants who were 66 to
75 years of age were recommended for statin treatment (90.3%). The ﬁxed 7.5% threshold had relatively low sensitivity
for capturing 10-year events in younger women and men (40 to 55 years of age). Sensitivity of the recommendations was
substantially improved when the treatment threshold was reduced to 5% in participants who were 40 to 55 years of age.
Among older adults (66 to 75 years of age), speciﬁcity was poor, but when the treatment threshold was raised to 10% in
women and 15% in men, speciﬁcity signiﬁcantly improved, with minimal loss in sensitivity.
CONCLUSIONS Cholesterol treatment recommendations could be improved by using individualized age- and sex-speciﬁc
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ABBR EV I A T I ON S
AND ACRONYMS
CVD = cardiovascular disease
NPV = negative
predictive value
PPV = positive predictive value
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1634These latest guidelines increase the num-
ber of adults in the United States re-
commended for statin therapy by nearly
13 million (1,2). The majority of the increase
is among adults 60 years of age or older, in
whom statin therapy is now recommended
for 80% or more of patients (3). These newerguidelines base their primary prevention treatment
recommendations on the 10-year predicted CVD
risk model using the Pooled Cohort Equations.
The thresholds for therapeutic consideration were
selected on the basis of 3 statin primary prevention
trials: 1) MEGA (Primary Prevention of Cardiovascular
Disease with Pravastatin in Japan); 2) AFCAPS/Tex-
CAPS (Air Force/Texas Coronary Atherosclerosis Pre-
vention Study); and 3) JUPITER (Justiﬁcation for the
Use of Statins in Prevention: An Intervention Trial
Evaluating Rosuvastatin). This selection of treatment
thresholds has been a point of controversy (4).
Ideally, one would want to treat a majority of those
patients who will subsequently develop a CVD event
(high sensitivity) while avoiding unnecessary treat-
ment among those patients not who will not develop
a CVD event (high speciﬁcity). Yet to date, it is un-
clear whether the guideline-recommended thresholds
achieve this goal among certain subgroups, such as
younger and older adults, and women and men.
Furthermore, it is possible that the performance of
the guidelines could be improved if treatment
thresholds were age and sex speciﬁc.SEE PAGE 1640Using data on adults from the Framingham Off-
spring Study, we estimated the sensitivity and spec-
iﬁcity of current ACC/AHA cholesterol treatment
guidelines for identifying adults at risk for CVD. We
also estimated the impact of varying the 10-year risk
thresholds that are used to identify adults for statin
therapy across age and sex groupings, to determine
how sensitivity and speciﬁcity may be affected by
using different risk thresholds.
METHODS
Our study population included adults from the Fra-
mingham Offspring Study, a longitudinal population-
based study that started in 1975, enrolling the
children of the original Framingham Heart Study
cohort and their spouses. We evaluated adults 40 to
75 years of age who were free of CVD at examination
cycle 3 or 6. Baseline characteristics (at examination
3 or 6), including blood pressure, blood pressure
treatment, diabetes status, smoking status, sex, and
lipid levels, were used to calculate a person’s 10-yearestimated risk on the basis of the Pooled Cohort
Equations. We excluded those adults with data
missing for variables in the Pooled Cohort Equations
(n ¼ 43). The basis of the statin treatment recom-
mendations was the 2013 ACC/AHA cholesterol
guideline (1). The number and percentage of adults
recommended for statin therapy were ﬁrst cal-
culated on the basis of the 2013 ACC/AHA cholesterol
guideline for all patients and then calculated
by age-speciﬁc (40 to 55 years, 56 to 65 years,
and >65 years) and sex-speciﬁc (women and men)
subgroups.
Adults were followed prospectively for new-onset
CVD events over the subsequent 10 years. These
events were deﬁned as a nonfatal myocardial
infarction, death from coronary heart disease, fatal
or nonfatal stroke, peripheral arterial disease, or
heart failure. The sensitivity, speciﬁcity, positive
predictive value (PPV), and negative predictive
value (NPV) of the guideline statin treatment rec-
ommendations were calculated on the basis of a
patient’s predicted likelihood for subsequent CVD
events, while taking into account the time-to-event
nature of the data (5). Analyses were stratiﬁed by
age (40 to 55 years, 56 to 65 years, and 66 to 75
years) and sex. Next, we varied the treatment
threshold for statin therapy from 3% to 20% and
determined the effect these changes had on guide-
line performance characteristics (e.g., sensitivity,
speciﬁcity, PPV, NPV).
Framingham Study participants provided written
informed consent for participation. This analysis was
approved by the Duke University Institutional Review
Board. All analyses were performed using SAS soft-
ware version 9.3 (SAS Institute, Inc., Cary, North
Carolina).
RESULTS
Our study population included 3,685 adults; their
average age was 57.2 years. Table 1 shows the
characteristics of the study population at the
“baseline” visit (examination 3 or examination 6).
Overall, 46.8% of adults met criteria for statin
therapy on the basis of the 10-year risk threshold of
7.5% used in the current guidelines. Treatment
recommendations varied substantially by age and
sex. Among adults 40 to 55 years of age, 21.0% met
criteria for statin therapy, compared with 55.2% of
adults 56 to 65 years of age and 90.3% of adults 66
to 75 years of age. The 10-year CVD event rate also
increased across age groups (12.5%, 17.5%, and
23.0%, respectively), but not as sharply as the rate
at which statin therapy was recommended. In
TABLE 1 Characteristics of the Study Population
All Adults Men Women
Age
40–55 yrs
Age
56–65 yrs
Age
66–75 yrs
n 3,685 1,715 1,970 1,663 1,280 742
Age, yrs 57.2 57.2 57.3 49.2 60.4 69.6
Male 46.5 46.5 47.3 45.3
Hypertension 40.0 44.1 36.4 26.6 45.3 60.8
SBP, mm Hg 128.4 130.5 126.7 121.8 131.5 137.9
DBP, mm Hg 76.9 79.2 74.8 77.0 77.6 75.5
BP treatment 24.4 26.1 22.9 14.9 28.0 39.4
Non–HDL-C, mg/dl 159.2 161.4 157.2 156.0 162.3 161.1
Total cholesterol, mg/dl 210.5 205.5 214.9 206.8 214.1 212.4
LDL-C, mg/dl 131.7 132.5 130.9 129.6 133.6 132.9
Cholesterol treatment 7.9 8.9 7.1 3.5 9.3 15.4
Diabetes 8.8 10.5 7.3 5.6 9.9 13.9
Smoking 18.9 19.0 18.8 24.7 16.5 10.0
BMI, kg/m2 27.6 28.3 27.1 27.5 27.8 27.6
10-year CVD observed rate 16.3 22.6 11.0 12.5 17.5 23.0
Statin recommended* 46.8 63.1 32.6 21.0 55.2 90.3
Values are mean or % (when no measurement is given), unless otherwise indicated. *Statin recommendation on
the basis of current guidelines.
BMI ¼ body mass index; BP ¼ blood pressure; CVD ¼ cardiovascular disease; DBP ¼ diastolic blood pressure;
HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; SBP ¼ systolic blood
pressure.
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1635women, the 10-year CVD rate was 11.0% versus
22.6% in men.
Tables 2 and 3 display the proportion of women
and men, respectively, recommended for statin
therapy, along with sensitivity, speciﬁcity, PPV, and
NPV of the guidelines on the basis of varying treat-
ment thresholds ranging from 3% to 20%, stratiﬁed by
age group. Differences in sensitivity and speciﬁcity by
age group in women and by age group in men are
shown in the Central Illustration.
In younger women and younger men (40 to
55 years of age), the guideline sensitivity for iden-
tifying adults who would develop CVD over the
next 10 years by using a cutoff of 7.5% was rela-
tively low, with only 36% of future cases identiﬁed
as treatment candidates in women and 49% of
future cases identiﬁed in men. Reducing the 10-year
risk threshold to 5% in women and men who were
40 to 55 years of age markedly improved sensitivity
(from 36% to 48% in women and from 48% to 71%
in men), with only a modest reduction in speciﬁcity
(90% to 87% in women and 72% to 56% in men).
More marked differences were seen in guideline
performance between men and women who were
56 to 65 years of age. Because 84% of men were rec-
ommended for statins in this age group at a cutoff
of 7.5% versus only 29% of women, sensitivity
was markedly higher in men compared with women
(90% vs. 49%, respectively). Using a risk threshold
of 7.5%, the guidelines were able to identify 9 in
10 men who would develop CVD over the next
10 years, but fewer than 1 in 2 women. When the
optional cutoff of 5% for statin use was extended
to women 56 to 65 years of age, sensitivity improved
to 65%.
In men 66 to 75 years of age, guideline sensi-
tivity and speciﬁcity varied little across treatment
thresholds because nearly all men in this age group
were recommended for statin therapy—even at a risk
threshold of 10% (97% recommended). Conse-
quently, speciﬁcity for a threshold of 10% or less
was extremely low (3%). Raising the 10-year risk
cutoff in older men to 15% led to a reduction in the
number of men recommended for statin therapy
(97% to 89%), with no change in sensitivity (96% to
96%) but improved speciﬁcity (3% to 14%). Even
when the threshold was increased to 20% (thereby
reducing the number treated with a statin to 68%),
sensitivity was reduced only to 87%, whereas spec-
iﬁcity improved to 40%. Similarly, among older
women, increasing the threshold from 7.5% to 10%
reduced the sensitivity only slightly from 95%
to 87%, but it nearly doubled the speciﬁcity from
17% to 34%.DISCUSSION
The newest ACC/AHA cholesterol guidelines sub-
stantially increase the number of individuals recom-
mended for statin therapy, particularly among older
women and men and among adult men of all ages.
Our study evaluated the treatment thresholds used by
the new guidelines to determine the number treated
who are likely to develop actual CVD events over the
next decade. We found that guideline treatment
performance varied in clinically signiﬁcant ways
across age- and sex-speciﬁc groups. Existing thresh-
olds had decreased sensitivity for predicting future
CVD events in women and younger adults, and they
had poor speciﬁcity for predicting such events in men
and older adults. Most importantly, we found that
guideline treatment performance could be improved
by selecting age- and sex-speciﬁc thresholds for
statin initiation.
Previous work has questioned the accuracy of
the Pooled Cohort Equations in predicting 10-year
atherosclerotic CVD risk, with criticism focusing on
the calibration and discrimination of the risk esti-
mates (6,7). However, as applied in the new AHA/ACC
cholesterol guidelines, the Pooled Cohort Equations
are used not to predict precise risk, but rather to
stratify adults into “high-risk” ($7.5% 10-year risk) or
“low-risk” categories using binary risk categories.
Therefore, the continuous precision of the Pooled
TABLE 2 Percentage of Women Recommended for
Statin Therapy and Guideline Performance on the Basis of
Varying Risk Cutoffs
10-yr
Threshold
% Meeting
Treatment
Threshold Sensitivity Speciﬁcity PPV NPV
All ages
20% 15 35 88 26 92
15% 18 41 85 25 92
10% 26 53 77 23 93
7.5% 33 61 71 21 94
5% 43 72 60 18 94
4% 49 78 54 17 95
3% 57 85 47 16 96
Age 40–55 yrs
20% 9 23 92 18 94
15% 9 23 92 18 94
10% 10 27 91 19 94
7.5% 11 36 90 23 95
5% 16 48 87 22 95
4% 19 54 84 21 96
3% 25 61 78 18 96
Age 56–65 yrs
20% 15 31 88 24 91
15% 15 31 87 23 91
10% 20 41 82 23 91
7.5% 29 49 73 19 92
5% 47 65 55 16 92
4% 59 78 43 15 94
3% 73 91 29 14 96
Age 66–75 yrs
20% 27 47 77 32 87
15% 43 67 63 29 89
10% 69 87 34 23 92
7.5% 85 95 17 21 93
5% 98 99 3 19 89
4% 99 99 1 18 67
3% 99 99 1 18 67
Values are %.
NPV ¼ negative predictive value; PPV ¼ positive predictive value.
TABLE 3 Percentage of Men Recommended for Statin Therapy
and Guideline Performance on the Basis of Varying Risk Cutoffs
10-yr
Threshold
% Meeting
Treatment
Threshold Sensitivity Speciﬁcity PPV NPV
All ages
20% 27 43 77 35 82
15% 38 54 67 32 83
10% 52 66 51 28 84
7.5% 63 77 41 27 85
5% 75 88 29 27 89
4% 81 92 22 26 90
3% 87 95 16 25 92
Age 40–55 yrs
20% 12 18 89 28 83
15% 14 23 88 30 83
10% 21 34 82 31 85
7.5% 32 48 72 28 86
5% 49 71 56 27 89
4% 60 80 44 25 91
3% 73 90 30 23 93
Age 56–65 yrs
20% 24 37 80 38 80
15% 40 55 65 34 82
10% 68 76 35 27 82
7.5% 84 90 18 26 85
5% 96 99 5 25 92
4% 98 99 3 25 93
3% 98 99 2 25 92
Age 66–75 yrs
20% 68 87 40 37 89
15% 89 96 14 31 91
10% 97 96 3 28 63
7.5% 97 96 3 28 63
5% 97 96 3 28 63
4% 97 96 3 28 63
3% 97 96 3 28 63
Values are %.
Abbreviations as in Table 2.
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1636Cohort Equations may actually be less important
than its ability to divide patients appropriately into
those above and below a particular risk threshold.
Our objective was not to examine the calibration of
the Pooled Cohort Equations, but rather to focus
on the practical issue of altering statin treatment
thresholds by age- and sex-speciﬁc groups to deter-
mine the performance characteristics of these treat-
ment recommendations.
Our study highlights 2 key concerns regarding the
use of a ﬁxed risk threshold in any type of treatment
guideline. First, the 7.5% threshold adopted by the
current cholesterol guidelines may not be optimal for
identifying younger adults in need of statin therapy.
Using the “optional” 5% threshold, we observed animprovement in guideline performance sensitivity in
identifying younger adults (40 to 55 years of age) who
are at risk for premature CVD (Central Illustration).
This sensitivity improvement supports the use of
the optional 5% threshold proposed in the current
ACC/AHA guidelines. Furthermore, our results un-
derscore the importance of efforts aimed at
increasing the ability to detect younger adults
who are at increased risk for CVD, beyond what is
offered by current 10-year risk estimation methods.
Similarly, the sensitivity of the guidelines was
poor among women 56 to 65 years of age, a ﬁnding
suggesting that this is another group deserving
of improved risk prediction models. Measures of
subclinical disease, comprehensive lipid proﬁle,
CENTRAL ILLUSTRATION Age- and Sex-Speciﬁc Risk Thresholds to Guide Statin Therapy
The new blood cholesterol guidelines from the American College of Cardiology/American Heart Association base statin therapy recommen-
dations on a 10-year ﬁxed risk threshold of 7.5% for atherosclerotic cardiovascular disease (ASCVD). Varying the 10-year risk thresholds in
women (top) and men (bottom) of speciﬁc age groups correspondingly alters the performance of the recommendations in regard to sensitivity
and speciﬁcity.
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1638biomarkers, and algorithms focused on 30-year or
lifetime risk should be examined for their impact on
the sensitivity of future CVD detection, particularly
in these risk groups.
Our second major concern is that although most
older adults (66 to 75 years of age) were recom-
mended for statin therapy, that recommendation
was made signiﬁcantly more for men than for
women in this age group. Because most (9 in 10)
of the older men had a 10-year risk of 7.5%, the
speciﬁcity of this recommendation was poor among
older men, thus leading to high rates of potentially
unnecessary statin treatment. We found that
guideline speciﬁcity in older men can be substan-
tially improved with no impact on sensitivity by
raising the treatment threshold to 15%. Nonethe-
less, the high proportion of those patients recom-
mended for treatment and the low speciﬁcity
achieved in this age group suggest that efforts
should be dedicated to improving discrimination
between those who require statin treatment
and those who do not.
We found that a slight adjustment of classiﬁcation
thresholds can improve the overall operating char-
acteristics of the current ﬁxed 7.5% threshold
guideline. For example, when we used a lower
threshold of 5% in adults 40 to 55 years of age, a
7.5% threshold in those 56 to 65 years of age, a 10%
threshold in women 66 to 75 years of age, and a 15%
threshold in men 66 to 75 years of age, the overall
number of adults recommended for treatment
increased by only 2% (from 47% to 49%), whereas
the overall guideline sensitivity increased from 71%
to 77%, with only a small decrease in speciﬁcity
(from 58% to 56%).
We acknowledge that there is no such thing as
a perfect threshold; improved sensitivity for pre-
dicting future events comes with the tradeoff of
reduced speciﬁcity and vice versa. As a result, pro-
viders and patients must weigh potential risks of
statin therapy (including cost considerations) against
the perceived beneﬁt of these drugs when deciding
whether or not to use statin therapy for primary
prevention. As the guidelines suggest, the thresholds
proposed should be used as starting points in a
conversation between patients and providers, with a
focus on shared decision making; however, our
study demonstrates that these treatment thresholds
should not be ﬁxed at an arbitrary number, but
rather determined with consideration of a patient’s
age and sex.
STUDY LIMITATIONS. First, our study population,
adults in the Framingham Offspring Study, is notnationally representative. Given that the Pooled
Cohort Equations are race speciﬁc, similar analyses
using alternate, racially diverse populations should
be performed to evaluate the potential need for
race-speciﬁc thresholds as well. Second, because
adults in the Framingham Offspring Study contrib-
uted to the derivation cohort used for the Pooled
Cohort Equations, the Pooled Cohort Equations may
be more accurate in this population than in a na-
tionally representative cohort. Nevertheless, older
age and male sex have been shown to be risk fac-
tors for CVD across multiple cohorts, so the overall
magnitude and direction of our estimates (higher
sensitivity in older adults and men) are not likely
to change when applied to a broader sample.
Finally, adults included in our study were pre-
dominantly enrolled in the Framingham Offspring
Study in the 1990s. Contemporary changes in risk
factor distribution and improvements in CVD
prevention efforts may contribute to lower over-
all rates of CVD than in those studied in our
cohort. This would lead to an overestimation
of PPV and an underestimation of NPV but
should not affect guideline sensitivity and speci-
ﬁcity estimates.
CONCLUSIONS
Considering the Pooled Cohort Equations in the
context of current cholesterol guidelines highlights
how differences in the age- and sex-speciﬁc distri-
bution of adults recommended for statin therapy
affect guideline performance. Establishing age-and
sex-speciﬁc 10-year risk thresholds to identify
adults for statin therapy may improve the balance
between avoided CVD events and unnecessary
therapy, as well as enhance overall guideline
performance.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE: The decision to
begin statin therapy should be shared between patient and
provider and should consider differences in risk
and guideline performance related to age and sex.
TRANSLATIONAL OUTLOOK: More information about
age- and sex-speciﬁc CVD risk thresholds warranting
therapy could improve individualized implementation of
future cholesterol treatment guideline recommendations.
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